Roth Capital analyst Kyle Bauser initiated coverage of Microbot Medical (MBOT) with a Buy rating and $5.50 price target The firm says the company’s Liberty Endovascular Robotic System achieved FDA clearance in September and has begun commercial use in select U.S. hospitals ahead of a full market release in April 2026. Roth thinks the technology will be useful within procedures that require navigation of complex vascular anatomy while also reducing physical strain and radiation exposure.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBOT:
- Microbot Medical’s LIBERTY System Gains Momentum with Emory University Adoption and Strategic Market Release
- Microbot Medical Partners with Emory for Robotics Program
- Microbot Medical announces Emory University first hospital to adopt LIBERTY
- Microbot Medical’s Strategic Positioning and Growth Prospects Justify Buy Rating
- Microbot Medical Launches LIBERTY® System in U.S.